



Health Care Sector Spotlight: Obesity

Artisan Partners Growth Team

ARTISAN PARTNERS
Insights

For Institutional Investors Only—Not for Onward Distribution

A R T I S A N



P A R T N E R S

Investment Risks: Investments will rise and fall with market fluctuations and investor capital is at risk. Investors investing in strategies denominated in non-local currency should be aware of the risk of currency exchange fluctuations that may cause a loss of principal. These risks, among others, are further described on the last page, which should be read in conjunction with this material.

Health Care Sector Spotlight: Obesity

Our Team’s Approach to Biotechnology and Pharmaceutical Investing

Health care has always been an important area of opportunity for our team. Within the sector, we tend to find the pharmaceutical and biotechnology industries particularly interesting given the continuous innovation. However, investing in these new innovative therapies can be risky with binary outcomes driven by clinical trial results and Federal Drug Administration (FDA) approvals. This necessitates a disciplined and selective process.

To us, being selective means looking for companies with: 1) a de-risked asset, in other words, a drug that is already FDA approved or we have confidence it will be approved; 2) a multi-drug pipeline building upon an approved asset or platform technology; and 3) a balance sheet allowing the company to navigate the tricky drug approval environment. There are over 350 public pharmaceutical and biotechnology companies within the Russell 3000 and MSCI All Country World ex USA indices, yet we only own 14 companies across our four portfolios as of 9/30/2023.

What We Look for in Pharma/Biotech Companies



Source: Artisan Partners.

The Obesity Epidemic and Emergence of GLP-1 Treatments


One of the exciting areas our team has been researching is the emergence of obesity therapies. The global obesity epidemic is worsening.

For example, 40% of Americans have a body mass index of 30 or above, due to factors including poor diet, lack of physical activity and sedentary lifestyles. The Centers for Disease Control and Prevention estimates obesity led to medical costs of \$173bn in 2019 given its link to multiple physical and mental health issues, including high blood pressure, diabetes, heart disease, stroke, depression and anxiety disorders.

While other industries have capitalized on the obesity opportunity through products and services promoting healthier lifestyles, such as low-calorie food products and fitness trackers, the biotechnology and pharmaceutical industries have also recognized the potential. In recent years, the introduction of Glucagon-like peptide 1 (GLP-1) treatments has been gaining momentum. GLP-1 is an incretin hormone that helps regulate glucose levels and slows food absorption into the bloodstream. It is a potential therapeutic option for those with weight issues as these drugs allow people to feel full quicker and eat fewer calories without feeling hungry.

While challenges must be overcome before these medications become more widely available on the market—including logistical issues—their efficacy when taken correctly has been proven to lead to weight loss of 15%-20%. In comparison, bariatric surgery, which can lead to ~30% weight loss, requires an invasive procedure that is unappealing to many.

Exhibit 1: US Monthly GLP-1 Prescription Volumes




Source: Bloomberg, as of 31 Mar 2023.

Prescription volumes for top GLP-1 therapies have been ramping up in recent years, and there are estimates that this category could reach \$50bn in annual sales by 2030, versus \$2bn in 2021. The competitive landscape for GLP-1 treatments is intensifying, but we believe **Novo Nordisk**, a CropSM position within our Global Opportunities Strategy, is best positioned with multiple leading therapies: Ozempic, Saxenda and Wegovy.

Other Companies Exposed to This Secular Driver

We are always interested in the broader supply chain implications from big new secular trends. In the case of new obesity therapies, we believe they will create major opportunities for certain biomanufacturing suppliers. These drugs are administered as weekly injections done by the patient at home using “pen” devices common to insulin therapy. We believe the growth of this category represents an excellent opportunity for the companies who supply these pens, and we own two of them: **West Pharmaceutical Services** and **Gerresheimer**.



For illustrative purposes only.

Both companies are adding manufacturing capacity to support future obesity drug volumes, and our research indicates these suppliers are securing attractive terms with pharmaceutical companies worried about keeping up with future demand.

We are excited about both the potential volume growth and the margin expansion opportunity. For example, approximately 80% of West’s volumes are basic components that cost a few pennies and carry ~25% gross margins, while the other 20% of its volumes are from higher-value parts. These higher-value components are made of better-quality materials, may be pre-sterilized so they arrive at the customer’s manufacturing line ready to be used, and may also be inspected by machine vision cameras to avoid defects. These types of components are in demand from biotech and pharma companies that are launching new high-value biologic drugs (such as GLP-1s) to ensure there aren’t any packaging or storage problems. As a result, West can charge 50 cents or more and earn ~60% gross margins. The mix shift toward higher priced, higher margin products—a strategy also being pursued on the glass components side by Gerresheimer—is what makes the company such a compelling long-term investment. We think the volume potential of obesity drugs should accelerate that trend.

The growth of the GLP-1 market also further strengthens the already attractive long-term outlook for bioprocessing companies who provide products and services to help pharmaceutical companies produce and refine complex injectable therapies, such as biologics and peptides. While the hangover from the COVID-19 vaccine boom-bust cycle is making 2023 challenging for bioprocessing companies such as **Danaher**, **Repligen** and **Lonza**, we expect a return to strong growth in 2024 for these franchises driven by innovative injectable therapies.

The following stocks are sample holdings in each of the four portfolios Artisan Partners Growth Team manages, highlighting investment opportunities the team believes should benefit from the emergence of obesity therapies.

Holding	Description	Global Opportunities	Global Discovery	U.S. Mid-Cap Growth	U.S. Small-Cap Growth
West Pharmaceutical Services	A leading supplier of packaging components for injectable pharmaceuticals, including rubber stoppers, seals, and plungers.	■	■	■	
Gerresheimer	A leading producer of specialty glass and plastic products made for pharmaceutical companies.		■	■	
Lonza	One of the largest manufacturers and producers of active pharmaceutical ingredients for biologic and small molecule drugs as well as cell and gene therapies.	■			
Repligen	A leading supplier of equipment, consumables and services for biologic manufacturing needs.			■	■
Danaher	A science and technology company with sales from multiple strategic platforms, including bioprocessing.	■			

Holdings information as of 31 Dec 2023.

Artisan Partners Growth Team

The following team members contributed to this report



Matt Kamm, CFA
Portfolio Manager



Martin Jochmann
Associate Portfolio Manager



Ryan Tochiara
Analyst

Investment Process Highlights

We seek to invest in companies with franchise characteristics that are benefiting from an accelerating profit cycle and are trading at a discount to private market value.

Security Selection

We seek to identify companies with franchise characteristics that are selling at attractive valuations and are benefiting from an accelerating profit cycle. We look for companies that are well positioned for long-term growth, driven by demand for their products and services, at an early enough stage in their profit cycle to benefit from the increased cash flows produced by the emerging profit cycle.

Capital Allocation

Based on our fundamental analysis of a company's profit cycle, we divide the portfolio into three parts. GardenSM investments are small positions in the early part of their profit cycle that will warrant a more sizeable allocation once their profit cycle accelerates. CropSM investments are positions that are being increased to a full weight because they are moving through the strongest part of their profit cycle. HarvestSM investments are positions

that are being reduced as they near our estimate of full valuation or their profit cycle begins to decelerate. We believe that adhering to this process increases the likelihood of delivering upside participation with downside protection.

Broad Knowledge

We overlay security selection and capital allocation with the capability to invest opportunistically across the entire global equity spectrum. It is our goal to have broad knowledge of the global economy to ensure that we are able to find growth wherever it occurs. This capability extends from the design of our team, which leverages the broad experience of the portfolio managers and the deep expertise of the analysts on the team.

Team Overview

We believe deep industry expertise, broad investment knowledge, a highly collaborative decision-making process and individual accountability are a powerful combination. Since the inception of the team in 1997, we have been committed to building a team of growth investors that retains these attributes and is solely dedicated to our process and approach.

For more information: Visit www.artisanpartners.com

Investment Risks: International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging and less developed markets, including frontier markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period. These risks, among others, are further described in Artisan Partners Form ADV, which is available upon request.

Unless otherwise indicated, the Artisan Strategy characteristics relate to that of an investment composite or a representative account managed within a composite. It is intended to provide a general illustration of the investment strategy and considerations used by Artisan Partners in managing that strategy. Individual accounts may differ, at times significantly, from the reference data shown due to varying account restrictions, fees and expenses, and since-inception time periods, among others. Where applicable, this information is supplemental to, and not to be construed with, a current or prospective client's investment account information. References to individual security performance relate to a representative account in the composite. Individual holding periods may differ.

This summary represents the views of the portfolio managers as of 30 Jun 2023. Those views may change and the Strategies disclaim any obligation to advise investors of such changes. For the purpose of determining the portfolios' holdings, securities of the same issuer are aggregated to determine the weight in the Strategy. The holdings mentioned above comprise the following percentages of a representative account within the Composite's total net assets as of 31 Dec 2023: Artisan Global Opportunities Strategy: West Pharmaceuticals Services Inc 1.3%, Novo Nordisk A/S 4.9%, Lanza Group AG 1.6%, Danaher Corp 2.0%, Artisan U.S. Mid-Cap Growth Strategy: West Pharmaceutical Services Inc 2.9%, Gerresheimer AG 1.6%, Repligen Corp 1.6%, Artisan Global Discovery Strategy: Gerresheimer AG 3.1%, West Pharmaceutical Services Inc 2.2%, Artisan U.S. Small-Cap Growth Strategy: Repligen Corp 2.1%. Portfolio holdings are subject to change without notice and are not intended as recommendations of individual securities. Securities named in the commentary, but not listed here are not held in the portfolio as of the date of this report.

MSCI All Country World Index measures the performance of developed and emerging markets. MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used to create indices or financial products. This report is not approved or produced by MSCI.

Russell 3000[®] Index measures the performance of roughly 3,000 US large-cap, midcap and small-cap companies. Frank Russell Company ("Russell") is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell[®] is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

The Global Industry Classification Standard (GICS[®]) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

The Artisan Partner's Growth Team's capital allocation process is designed to build position size according to its conviction. Portfolio holdings develop through three stages: GardenSM, CropSM and HarvestSM. GardenSM investments are situations where the team believes it is right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. CropSM investments are holdings where the team has gained conviction in the company's profit cycle, so positions are larger. HarvestSM investments are holdings that have exceeded the team's estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. HarvestSM investments are generally being reduced or sold from the portfolios.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

Artisan Partners Limited Partnership (APLP) is an investment adviser registered with the U.S. Securities and Exchange Commission (SEC). Artisan Partners UK LLP (APUK) is authorized and regulated by the Financial Conduct Authority and is a registered investment adviser with the SEC. APEL Financial Distribution Services Limited (AP Europe) is regulated by the Central Bank of Ireland. APLP, APUK and AP Europe are collectively, with their parent company and affiliates, referred to as Artisan Partners herein.

Artisan Partners is not registered, authorized or eligible for an exemption from registration in all jurisdictions. Therefore, services described herein may not be available in certain jurisdictions. This material does not constitute an offer or solicitation where such actions are not authorized or lawful, and in some cases may only be provided at the initiative of the prospect. Further limitations on the availability of products or services described herein may be imposed.

This material is provided for informational purposes without regard to your particular investment needs. This material shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

This material is only intended for investors which meet qualifications as institutional investors as defined in the applicable jurisdiction where this material is received, which includes only *Professional Clients* or *Eligible Counterparties* as defined by the Markets in Financial Instruments Directive (MiFID) where this material is issued by APUK or AP Europe. This material is not for use by retail investors and may not be reproduced or distributed without Artisan Partners' permission.

In the United Kingdom, issued by APUK, 25 St. James's St., Floor 3, London SW1A 1HA, registered in England and Wales (LLP No. OC351201). Registered office: Reading Bridge House, Floor 4, George St., Reading, Berkshire RG1 8LS. In Ireland, issued by AP Europe, Fitzwilliam Hall, Fitzwilliam Pl, Ste. 202, Dublin 2, D02 T292. Registered office: 70 Sir John Rogerson's Quay, Dublin 2, D02 R296 (Company No. 637966).


Australia: This material is directed at wholesale clients only and is not intended for, or to be relied upon by, private individuals or retail investors. Artisan Partners Australia Pty Ltd is a representative of APLP (ARBN 153 777 292) and APUK (ARBN 603 522 649). APLP and APUK are respectively regulated under US and UK laws which differ from Australian laws and are exempt from the requirement to hold an Australian financial services license under the Australian Corporations Act 2001 in respect to financial services provided in Australia.

Canada: This material is distributed in Canada by APLP and/or Artisan Partners Distributors LLC, which conduct activities in Canada under exemptions from the dealer, portfolio manager and investment fund manager registration requirements of applicable Canadian securities laws. This material does not constitute an offer of services in circumstances where such exemptions are not available. APLP advisory services are available only to investors that qualify as "permitted clients" under applicable Canadian securities laws.

© 2024 Artisan Partners. All rights reserved.

For Institutional Investors Only — Not for Onward Distribution

A R T I S A N



P A R T N E R S